Due to concern over long term safety of continuous treatment with cyclosporin, the aim of this 1-year study was to assess the effect of intermittent therapy with cyclosporin (Neoral Ò ) on the quality of life of patients suffering from chronic plaque psoriasis.
Introduction
The efficacy of cyclosporin in the treatment of psoriasis and its positive impact on patients' health-related quality of life (QOL) has been established in trials [1] [2] [3] . In particular, clearance of lesions has been achieved using low doses of cyclosporin (2.5-5 mg/kg bodyweight/day) [1, 2] . However, due to concern over long term safety of continuous treatment with cyclosporin, strategies for optimising treatment in order to limit renal dysfunction are necessary [4, 5] .
Many studies have shown the clinical benefits of a regime of intermittent therapy with cyclosporin [6, 7] , however none have investigated the impact on patients' QOL. This study was therefore carried out to investigate the effect of intermittent therapy on QOL of patients with chronic plague psoriasis over a period of 1 year, using a microemulsion formulation of cyclosporin called Neoral Ò .
Methods

Study design
This was a prospective UK 9-centre open study of patients with chronic plague psoriasis. Patients received up to three courses of cyclosporin (5 mg/ kg/day) each of 12 weeks maximum duration. Treatment was stopped upon achieving 90% reduction in area affected (remission), or at 12 weeks. However, patients failing to demonstrate a satisfactory response were withdrawn. Cyclosporin was recommenced upon a return to 75% of affected area compared with baseline, or, when the investigator or patient felt further treatment was required. This cycle was repeated up to three times and patients were followed up to 1 year. All relevant ethics committees approved the research protocol.
Subjects
Patients were males (n ¼ 26) and females (n ¼ 15), with chronic plague psoriasis who had been referred to dermatology outpatients clinic requiring a hospital based clearance treatment for their psoriasis. Patients' age had a median of 34 years (range: 18-61 years); median duration of psoriasis was 17 years (range: 2-31 years). Uncooperative patients and those incapable of completing the study were excluded.
Treatment
Patients were started on a dose of 5 mg/kg/day of a microemulsion formulation of cyclosporin A (Neoral Ò ) [8, 9] in two divided doses, chosen for its favourable relationship between rapid onset of action and degree of response [2, 10] . Dose reductions of 25% were made when necessary to prevent treatment related side effects. Active systemic or topical treatment was not permitted during the trial, however emollients and medicated shampoos were allowed.
Quality of life assessment
Patients' health-related QOL was evaluated using an established disease-specific instrument, the psoriasis disability index (PDI) [11] . This questionnaire contains 15 questions answered on a 1-7 linear analogue scale (i.e. 'not at all' to 'very much'). The 15 questions are grouped into five categories: daily activity (five items), work or school (three items), personal relationships (two items), leisure (four items) and treatment (one item). The PDI score is calculated by summing the scores for each question. Patients' assessment of their QOL using PDI was carried out at beginning and end of each cycle and at the end of the study (last follow-up).
Clinical assessment
The psoriasis area involvement and severity was measured using the well-established Psoriasis Area and Severity Index (PASI) method [12] at each baseline and treatment end for the three cycles and at the end of the study. A patient's PASI score is a measure of overall psoriasis coverage (a scale from 0 to 6: legs, body, arms and head) and severity (a scale from 0 to 4 for the four skin areas: itching, erythema/redness, scaling and thickness). These measures are then combined to give an overall score. In addition, the proportion of skin affected and disease activity were monitored. Subjects and investigators graded both overall treatment tolerability and efficacy on a five-point scale (i.e. very good to very poor) at the end of each treatment period.
Data management and analysis
All major analyses focused on the degree of change in the QOL scores from baseline to the end of the treatment period and to the last follow-up. Changes in PASI score, from first recorded value to last recorded, were also calculated. The changes in the QOL scores were assessed using non-parametric Wilcoxon matched pairs tests. Spearman's rank correlation coefficients investigated relationships between QOL elements and clinical assessments. p-Values were based on two-tailed tests, with p < 0.05 taken as statistically significant, except for multiple comparisons where p < 0.01 was used. The SPSS v7.5 statistical package [13] was used throughout.
Results
Characteristics of study completers/non-completers
Of the 41 patients enrolled in the study, 38 completed the first cycle. Of these 38, there were 33 who entered the second cycle, 28 of whom went on to complete cycle two. Cycle three was started by 16 people; the 12 who did not start cycle three included nine patients who had not relapsed by the end of the study. Five did not complete cycle three. Of the 41 patients who started the study, 21 failed to complete the study as planned. Five were withdrawn due to adverse events (none serious); five failed to achieve satisfactory response; four protocol violations; seven withdrew for personal reasons. An analysis of completers/non-completers gave no relationship with gender (p ¼ 0.205, v 2 test), age (p ¼ 0.271, Mann-Whitney test) or patient/investigator assessments of tolerability/efficacy in the first cycle (Mann-Whitney tests adjusted for multiple comparisons).
Treatment cycles
The cyclosporin dose range was 1.8-5.1 mg/kg/ day, with the mean dose range of all treatment periods being 4.2-4.8 mg/kg/day. In addition, the mean durations of treatment, in weeks, for the three treatment periods were 7.2 (SD ¼ 3.0), 8.0 (SD ¼ 3.2) and 7.4 (SD ¼ 3.2), respectively. The mean time between treatment periods one and two was 89.9 days and between periods two and three was 63.2 days. Nine people did not relapse in time for the third cycle, hence this decrease from 89.9 to 63.2 days results largely from a biased censoring of the data and not decreasing efficacy.
Changes in quality of life
Mean QOL scores at each cycle baseline, at the end of each treatment period and at last follow-up are presented in Table 1 and Figure 1 . All PDI category scores were greatly reduced (improved) during all three of the cycles. The improvements were less pronounced in later cycles as relapse is defined as return to 75% affected area at previous baseline, hence later cycles started with improved scores. Although, the QOL scores for all PDI categories were increased at the end of the last follow-up visit, compared to the end of each treatment cycle, they were still far better than at baseline. Mean PASI score improved by 53%, from 12.8 (SD: 7.6, n ¼ 41) at first baseline to 6.0 (SD: 4.0, n ¼ 33) at end of follow-up (p < 0.001). In addition, the proportion of skin affected and disease activity for each treatment period also showed significant improvement (p < 0.001). There was no correlation between patients' age and QOL in any of the three cycles.
Treatment tolerability/efficacy
The PDI scores correlated better with the patient's assessment of overall treatment tolerability than the investigator's assessment. Within each treatment cycle, the relationships between patient's and investigator's assessment of efficacy were always stronger than those of tolerability, tested using Spearman's correlation coefficients and the weighted j measure of agreement. An investigation of how assessments varied between cycles showed a significant correlation between the investigator's assessment of tolerability for cycles one and two (p ¼ 0.002), but not between cycles for any other assessments. This lack of correlation may be explained by the fact that 94% of all assessments were graded 'very good' or 'good'.
Discussion
A satisfactory QOL improvement of 80, 79.7 and 76% was achieved over the three treatment periods. This degree and consistency of QOL improvement throughout the three cycles, each of a maximum of 12 weeks treatment with this microemulsion formulation of cyclosporin (Neoral Ò ), is most encouraging (initial baseline of 35.2 to cycle 3 end of treatment of 5.2 -an improvement of 85%). Indeed, this is very different to previous experiences using original cyclosporin formulation both in its magnitude and consistency. The improvements seen in the clinical measures of psoriasis are also very encouraging and confirm previous studies.
Studies of this intermittent nature often suffer from a form of attrition bias, whereby those who do not respond well to the treatment are ethically removed from the study, hence biasing the results in subsequent cycles. However, of the 41 patients who entered our study, only five were withdrawn due to ineffective treatment; nine patients did not relapse in time to be included in the third cycle. In addition an analysis of completers/non-completers showed no relationship with gender, age or patient/investigator rating of treatment tolerability/ efficacy in the first cycle. Consequently it may be deduced, it is likely that attrition bias did not alter the conclusions. Since the protocol required that active systemic and topical treatments could not be used during the study, the inclusion of a placebo was judged unethical. As the improvements, in terms of both QOL and clinical parameters, are so marked during the cycles, this is not felt to be a major study limitation.
This study has demonstrated that intermittent therapy with cyclosporin (Neoral Ò ) improves QOL of patients with chronic plaque psoriasis and may offer a safe long term strategy for optimising treatment while limiting undesirable toxicities. It has also shown the PDI to be a very useful QOL tool in these studies. 
